Media Thread, page-10449

I listened to a couple of the interviews.
First off, I am a big fan of LC.
imho. Too many jargon such as allogenic, CD19, immunotherapies, obcarlytics, CAR T, etc.
maybe it pays to prepare talking points, or adopt the adage, "explain to me like I am a five year old"
Assume your audience having zero knowledge of cancer treatments.
Simplify the concepts, it is not an academic paper in a graduate program.
Don't assume your audience knows what immunitherapies are, let alone allogenic, CAR T etc.
Something like:
Majority of cancer treatments traditionally use radiation, chemicals (chemo), and surgeries.
Invoking our own immune system to fight cancer cells selectively, leaving healthy cells alone. Lighting up cancer cells so they can become visible and destroyed by cancer drugs.
We are working on finding the maximum dosages without toxicities... etc
The interviews are less than 10 minutes long and meant for general investors, not oncologists and researchers.
Just my 2cents.
dyor.
Go imugene go!
Go you good thing!
Enjoy your weekend, fellow travellers!